Study of Tremelimumab in Patients with Advanced Solid Tumors
Study identifier:D4884C00001
ClinicalTrials.gov identifier:NCT02527434
EudraCT identifier:2015-002934-32
CTIS identifier:N/A
Study Complete
Official Title
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
Medical condition
Urothelial bladder cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
64
Study type
Interventional
Age
18 Years - 150 Years
Date
Study Start Date: 02 Nov 2015
Primary Completion Date: 17 Feb 2018
Study Completion Date: 28 Mar 2023
Study design
Allocation: N/A
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2023 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: treme mono to be sequenced to MEDI4736 mono or combination tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD) | Biological/Vaccine: Tremelimumab monotherapy IV infusion Biological/Vaccine: MEDI4736 monotherapy IV infusion Biological/Vaccine: MEDI4736 + tremelimumab combination therapy IV infusion |
Contacts
Investigators
Principal Investigator
Sharma Padmanee
Anderson Cancer Center, the University of Texas
